Robert Parkinson, Baxter

Chairman and CEO, Baxter International
Total 2014 Compensation: $15.30 million

Baxter ($BAX) chief Robert Parkinson makes a perennial appearance on the list of biopharma's top-paid CEOs, and this year is no exception, despite a slight dip in his overall compensation.

Parkinson netted $15.3 million for 2014, a step down from the $16.2 million he picked up in 2013 and the $17.5 million he pocketed the year before that. While his base salary stayed steady at $1.54 million, and his annual cash bonus shot up 17% to $3.17 million, his stock awards weren't so lucky. Parkinson collected share awards worth $3.6 million, just over half of the $6.8 million he garnered in 2013. Parkinson's pension grew by $2.47 million, and he got options worth $4.54 million.

What Parkinson didn't get--that some of his fellow Baxterites did--was a retention bonus related to the spinoff of the company's biopharma business, Baxalta. The execs leading that charge collected share grants that vest in three years, provided they stick around.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - Robert Parkinson | 20 Highest-Paid Biopharma CEOs of 2012 - Robert Parkinson - Baxter International
Baxter pays execs more than $8.5M to stick it out through pharma spinoff
Baxter picks HQ for biopharma spinoff, and it's just up the road
Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon
Meet Baxalta, the pharma spinoff Baxter plans to unleash in 2015

Robert Parkinson, Baxter

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.